Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036361 · ClinicalTrials.gov registry record · Phase 3
Broad Effectiveness: Study With Aripiprazole
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
NCT00036361 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 444 participants.
The verdict
NCT00036361, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036361
The ClinicalTrials.gov registry entry for NCT00036361 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00036361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036361 about?
NCT00036361 is a clinical study titled "Broad Effectiveness: Study With Aripiprazole". The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
What is the current status of trial NCT00036361?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2002-07. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036361?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00036361?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.